CD274 and triple-negative breast carcinoma: Moreover, the second major effector pathway of RAS, the PI3K/AKT pathway, also seems to play a role in regulating PD-L1 expression, as inhibition of either AKT or mTOR resulted in decreased PD-L1 levels in triple negative breast cancer (TNBC)[85].